Phathom Pharmaceuticals Highlights New Cost-Effectiveness Data and Growing Clinical Interest in VOQUEZNA® (vonoprazan) at ACG 2026
Phathom presented new predictive cost-effectiveness data at ACG 2026 projecting VOQUEZNA to be cost-effective versus PPIs in Erosive GERD, with potential healthcare savings at estimated net price. At WAC price, projected ICERs were $28,402 per QALY for the overall and $18,878 per QALY for the severe Erosive GERD population, both well below the standard $100,000 cost-effectiveness threshold.
Key figures
- Drug Name
- VOQUEZNA (vonoprazan)
- Independent abstracts
- 38
- Icer severe erosive gerd wac
- $18,878 per QALY
- Icer overall erosive gerd wac
- $28,402 per QALY
- Real world vonoprazan patients
- 1304
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.